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Abstract
Objective: To pinpoint the earliest cellular defects underlying seizure onset (epi-
leptogenic period) during perinatal brain development in a new zebrafish model of 
Dravet syndrome (DS) and to investigate potential disease-modifying activity of the 
5HT2 receptor agonist fenfluramine.
Methods: We used CRISPR/Cas9 mutagenesis to introduce a missense mutation, 
designed to perturb ion transport function in all channel isoforms, into scn1lab, the 
zebrafish orthologue of SCN1A (encoding voltage-gated sodium channel alpha subu-
nit 1). We performed behavioral analysis and electroencephalographic recordings 
to measure convulsions and epileptiform discharges, followed by single-cell RNA-
Seq, morphometric analysis of transgenic reporter-labeled γ-aminobutyric acidergic 
(GABAergic) neurons, and pharmacological profiling of mutant larvae.
Results: Homozygous mutant (scn1labmut/mut) larvae displayed spontaneous seizures 
with interictal, preictal, and ictal discharges (mean = 7.5 per 20-minute recording; 
P < .0001; one-way analysis of variance). Drop-Seq analysis revealed a 2:1 shift in 
the ratio of glutamatergic to GABAergic neurons in scn1labmut/mut larval brains versus 
wild type (WT), with dynamic changes in neuronal, glial, and progenitor cell popula-
tions. To explore disease pathophysiology further, we quantified dendritic arboriza-
tion in GABAergic neurons and observed a 40% reduction in arbor number compared 
to WT (P < .001; n = 15 mutant, n = 16 WT). We postulate that the significant re-
duction in inhibitory arbors causes an inhibitory to excitatory neurotransmitter imbal-
ance that contributes to seizures and enhanced electrical brain activity in scn1labmut/
mut larvae (high-frequency range), with subsequent GABAergic neuronal loss and 
astrogliosis. Chronic fenfluramine administration completely restored dendritic arbor 
numbers to normal in scn1labmut/mut larvae, whereas similar treatment with the ben-
zodiazepine diazepam attenuated seizures, but was ineffective in restoring neuronal 
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1 |  INTRODUCTION
Dravet syndrome (DS) is a severe, intractable, pediatric 
epileptic encephalopathy.1 Approximately 70%-80% of pa-
tients carry de novo mutations in SCN1A, which encodes the 
voltage-gated sodium channel α1 subunit (Nav1.1).
2 Gene 
variants for SCN2A, SCN8A, GABRA1, or STXBP1 have also 
been implicated in DS-like epileptic encephalopathies, mak-
ing DS a heterologous disease, with high phenotypic vari-
ability among patients.3,4 Seizure onset is typically provoked 
by fever, usually within the first year of life.1 Patients ex-
hibit prolonged, frequent, and diverse types of seizures, from 
febrile or afebrile, to generalized myoclonic and/or absence 
seizures5 that are refractory to current antiseizure drugs.
Human and mouse Nav1.1 is predominantly expressed in 
parvalbumin-positive γ-aminobutyric acid (GABA) interneu-
rons,6 in brain structures playing a critical role in seizure gen-
eration and spread,7,8 such as the hippocampus or cortex.9,10 
Nav1.1 haploinsufficiency impairs Na
+ currents and action 
potential firing of GABAergic interneurons, leading to an 
elevated excitation/inhibition ratio in forebrain structures.6 
Moreover, functional and structural dentate gyrus deficits in 
the hippocampal network parallel spontaneous seizure onset. 
In particular, dentate gyrus granule cells exhibited reduced 
dendritic arborization and increased spine density.11
In addition to stiripentol and cannabidiol, now approved 
by the US Food and Drug Administration as add-on therapy 
for DS, fenfluramine (FEN) has emerged as a promising ther-
apeutic candidate.12,13 FEN, an amphetaminelike drug initially 
introduced into the market as an appetite suppressant, acts as an 
serotonin (5-hydroxytryptamine [5-HT]) receptor type 2A, 2B, 
and 2C agonist and a strong inducer of 5-HT release. Recently, 
FEN was proposed to exert antiseizure activity through al-
losteric modulation of the sigma-1 receptor.14 An open-label 
clinical trial using a clinically confirmed cohort of DS pa-
tients indicated that seven of 10 patients taking FEN were sei-
zure-free for >1 year (mean = 6 years15). Results from phase 
3 clinical trials (FEN hydrochloride; Fintepla, ZX008) showed 
64% seizure reduction in children taking 0.8 mg/kg/d,15 which 
corroborates the report by Zhang et al,16 who demonstrated 
FEN efficacy in decreasing mean duration and frequency of 
epileptiform discharges in a zebrafish scn1a knockdown model. 
Due to concerns associated with FEN and its potential to induce 
cardiac valve disease and/or pulmonary hypertension,17 it was 
withdrawn from the market in 1997. However, the latest ret-
rospective study indicated that long-term treatment with FEN 
(27 years) did not increase risk of cardiac valvulopathy or pul-
monary hypertension.18
Zebrafish are now a recognized model of epilepsy, with 
genetic and chemically induced models able to recapitulate 
characteristic features of epileptiform activity.19,20 Here, we 
introduced an indel mutation into scn1lab, the zebrafish or-
thologue of SCN1A. We undertook a comprehensive analysis 
of scn1labmut/mut larvae to obtain insight into the earliest neu-
rodevelopmental and epileptogenic consequences of scn1lab 
dysfunction. Additionally, due to lack of knowledge about the 
early chronic effects of FEN usage in DS patients, we aimed 
to clarify whether and how FEN could counteract neurode-
velopmental changes in scn1labmut/mut brains.
2 |  MATERIALS AND METHODS
2.1 | Zebrafish husbandry
Wild-type (WT) adult zebrafish (Danio rerio; AB strain; 
ZIRC) were maintained at 28.5°C on a 14-h/10-h light/dark 
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cytoarchitecture. BrdU labeling revealed cell overproliferation in scn1labmut/mut larval 
brains that were rescued by fenfluramine but not diazepam.
Significance: Our findings provide novel insights into early mechanisms of DS 
pathogenesis, describe dynamic cell population changes in the scn1labmut/mut brain, 
and present first-time evidence for potential disease modification by fenfluramine.
K E Y W O R D S
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Key Points
• Zebrafish scn1labmut/mut larvae display dynamic 
neuronal and glial cell population changes, includ-
ing GABAergic neuronal loss and astrogliosis
• scn1labmut/mut larvae display strongly reduced den-
dritic arborization of GABAergic neurons and cell 
hyperproliferation
• Chronic fenfluramine treatment rescued the ob-
served arborization and cell hyperproliferation 
defects, whereas diazepam treatment did not
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cycle under standard aquaculture conditions, and fertilized 
eggs were collected via natural spawning. Embryos were 
raised in embryo medium (E3; 1.5 mmol/L HEPES, pH 7.6, 
17.4 mmol/L NaCl, 0.21 mmol/L KCl, 0.12 mmol/L MgSO4, 
and 0.18 mmol/L Ca[NO3]2), under the same conditions as 
adults. All experiments were approved by the Norwegian 
Food Safety Authority experimental animal administration's 
supervisory and application system (FOTS-18/106800-1).
2.2 | Zebrafish lines
The scn1lab (c.439_441delATG;443_445delCGC, 
p.M147_L149delinsI) line, hereafter scn1labmut/mut, was 
generated using CRISPR/Cas9 mutagenesis. The identi-
fied founder carried a 6-nucleotide deletion within exon 
4 (gRNA sequence: CTGCGCCTTCATGACGCTCAG, 
Figure S1A). This deletion produced a double amino acid 
(aa) deletion (Met, Leu) and a single aa change (Thr->Ile; 
Figure 1A). The aa sequence changed from FMTLSNP 
to FISNP and affects the ion transport domain (http://
www.ebi.ac.uk/inter pro/entry/ IPR00 5821; Figure S1B). 
Dlx5/6:Gal4-T2A-gfp were generated by coinjecting the 
iTol2_Dlx5/6:Gal4-T2A-gfp plasmid with transposase 
mRNA. This plasmid was obtained by cloning the dlx6a-
1.4kbdlx5a/dlx6a:GFP sequence into a pminiTol2 vec-
tor (Addgene #31829).21 The sequence was taken from 
the plasmid pcs-dlx6a-1.4kbdlx5a/dlx6a:GFP (gift, Mark 
F I G U R E  1  Development of scn1labmut/mut zebrafish model by CRISPR/Cas9 technique and its characterization. A, Amino acid and 
nucleotide sequence of scn1lab in zebrafish wild type (WT) and scn1labmut/mut, and orthologues in human (SCN1A) and mouse (Scn1a). Dots 
indicate identical nucleotides, dashes indicate deletions, and stars indicate identical nucleotides in all four sequences. B, WT and scn1labmut/mut 
larvae at 5 days postfertilization (dpf). Increased pigmentation is observed in mutants. Scale bars = 1 mm. C, Example of local field potential 
(LFP) recording obtained from the scn1labmut/mut tectum at 5 dpf, showing a seizure event with preictal and ictal phase. D, scn1labmut/mut larvae at 
5 dpf show an increased number of seizures over a 20-minute period compared to WT larvae or scn1labwt/mut siblings. A low number of seizures 
were observed in WT larvae, likely caused by needle insertion into the optic tectum. scn1labwt/mut displayed a larger number of seizures on average 
than WT larvae, but more interindividual variability was observed, with some larvae displaying no seizures, whereas others were affected to the 
same extent as homozygous larvae. No significant difference in the number of seizures was observed between WT larvae and scn1labmut/mut larvae 
treated with valproic acid (VPA), fenfluramine (FEN), or diazepam (DZP), indicating efficacy of these drugs in reducing the number of seizures to 
background levels. Significance was calculated using one-way analysis of variance with Tukey post hoc test (*P < .05, **P < .01, ***P < .001, 
****P < .0001) or unpaired, two-tailed t test (§P < .05). E, Power spectrum analyses of LFP recordings performed under dark conditions, or 
under a 10-Hz flashing light stimulus. The energy profile of scn1labmut/mut larvae differs significantly from WT and scn1labwt/mut siblings in both 
conditions. A Kolmogorov-Smirnov test was used to calculate significance
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Ekker). Subsequently, a polymerase chain reaction (PCR) 
fragment containing Gal4-T2A was inserted in-frame with 
green fluorescent protein by blunt end ligation into the 
final plasmid.
2.3 | Locomotor tracking
Locomotor activity was assessed as previously described,20 
with modifications. Four- and 7-days postfertilization 
(dpf) larvae were placed in 48-well plates (one larva/well) 
containing 300 µL medium and habituated for 15 minutes 
to the apparatus (ZebraBox, Viewpoint). Larvae were 
tracked for 60 minutes in light/dark phase, with 5-minute 
integration intervals. Measurements were performed at the 
same daytime period. Distance covered by each larva was 
recorded in millimeters. Two independent experiments 
were performed (n  =  44-48/group/phase), and the data 
were pooled.
2.4 | Local field potential recordings
Recordings were obtained from tecta at 4 and 5 dpf as de-
scribed.20 Seizure detection was performed through visual 
inspection and automated using a custom-written R script 
to minimize bias and artifacts due to muscle contractions. 
Recorded frequencies were categorized into three bands (1-
100, 100-250, and 250-500 Hz). If amplitude exceeded 3× 
background, the event was considered a seizure. This method 
was based on high-frequency oscillations (>100 Hz) as a re-
ported marker of epileptic activity.22 Power spectrum was 
analyzed using Clampfit 10.2 software (Molecular Devices). 
Four-minute-long recordings were used for computing the 
power spectrum from larvae at 5 dpf, and each condition 
was averaged per group. Light stimuli were generated with a 
custom-made device comprising an Arduino board sending a 
10-Hz sinusoidal wave to a transistor, which in turn powered 
a 2-W light-emitting diode emitting white light. Light was 
delivered via optic fiber to the recording stage.
2.5 | Real-time quantitative PCR
Heads of 6-dpf anesthetized larvae were collected in pools 
of 10 for RNA extraction. RNA was purified using TRIzol, 
and cDNA was synthesized using the SuperScript IV First-
Strand Synthesis System (Invitrogen). cDNA was ampli-
fied using PowerUp SYBR Green Master Mix (Applied 
Biosystems) according to the manufacturer's instructions. 
Relative enrichment was computed according to the 2−∆∆t 
method.23 Expression levels were normalized against 








2.6 | Single-cell transcriptomics
Brain dissections, cell dissociations, encapsulation, and gen-
eration of microfluidic Drop-Seq chips were performed in ac-
cordance with the Drop-Seq protocol24 as described (detailed 
in Supplementary Methods in Data S1).
2.7 | Bioinformatics
Sequencing data were processed by the Drop-Seq bioin-
formatics pipeline (v1.13), and reads were mapped against 
genome version GRCz11.92, resulting in corresponding 
digital expression matrices. Data analysis was performed 
by Monocle (v2.4.0) in R (v3.4.4) following the standard 
workflow for quality control, dimension reduction, and dif-
ferential expression analysis (see Supplementary Methods 
in Data S1).
2.8 | Imaging and quantification of arbors
To visualize GABAergic neurons, scn1labwt/mut fish were 
crossed with Dlx5/6:Gal4-T2A-gfp/UAS:nfsb-mCherry 
reporter line. Adults were then in-crossed for generat-
ing scn1labmut/mut. For controls, Dlx5/6:Gal4-T2A-gfp/
UAS:nfsb-mCherry fish were crossed with WT. Larvae 
were treated from 1 dpf with 0.003% phenylthiourea, to 
prevent pigmentation. FEN (50  µmol/L) or diazepam 
(DZP; 10 µmol/L) was added to E3 medium at 3 dpf and 
replaced daily until 6 dpf. Larvae were anesthetized in 
0.001% tricaine (Sigma), fixed for 3  hours at room tem-
perature with 4% paraformaldehyde, mounted on glass 
slides, and imaged using confocal microscopy. A dorsal 
z-stack of the optic tectum was collected using a ×40 lens 
and a z-resolution of 0.44 μm. For Sholl analysis,25,26 im-
ages were filtered using the 3D-Median filter in ImageJ. A 
z-projection of the tectum was generated, and the resulting 
image was converted to a thresholded binary image. The 
extent of arborization was quantified using Sholl analysis 
(plug-in; http://imagej.net/Sholl_Analysis). The number of 
intersections was normalized against the number of neu-
rons quantified in the imaged area, and this value was used 
for statistical analysis.
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2.9 | BrdU immunohistochemistry
BrdU labeling was performed as described in Supplementary 
Methods (Data S1).
2.10 | Statistical analysis
Data were analyzed using GraphPad Prism 7.05. For multi-
ple comparisons, one-way analysis of variance followed by 
Tukey or Sidak post hoc test was used. Students unpaired t 
test or Kolmogorov-Smirnov test was performed if necessary. 
For single-cell RNA-Seq (scRNA-Seq) analysis, Bonferroni 
compensation for multiple testing was used when applicable.
3 |  RESULTS
3.1 | scn1labmut/mut larvae recapitulate 
features of DS
We generated a zebrafish line, using CRISPR/Cas9 mutagen-
esis, carrying a double aa deletion and single aa substitu-
tion in the first ion transport domain of scn1lab (Figure S1). 
Morphologically, scn1labmut/mut larvae phenocopied previ-
ously described zebrafish scn1lab loss-of-function models, 
displaying hyperpigmentation from 4 dpf and uninflated 
swim bladders.16,27 At 5 dpf, a "kink" posterior to the trunk 
became evident and larvae struggled to maintain an upright 
posture (Figure 1B). Homozygotes survive until 14 dpf, 
whereas heterozygotes breed well and remain healthy up to 
18  months. We assessed locomotor activity16,19,20 at 4 and 
7 dpf. scn1labmut/mut larvae were more active and traveled 
greater distances in light phase compared to WT. However, 
whereas WT siblings tested in dark phase increased locomo-
tor activity, scn1labmut/mut larvae displayed minimal increase 
in movement in dark conditions (Figure S2). Touch response 
in 5-dpf scn1labmut/mut larvae was comparable to WT, with 
delayed touch response in two of 24 mutant larvae versus 
one of 24 WT larvae (data not shown). Tectal field record-
ings indicated that both scn1labmut/mut and scn1labwt/mut lar-
vae displayed seizures starting from 4 dpf (Figure 1D, Figure 
S3). Five-days-postfertilization scn1labmut/mut larvae (n = 17) 
displayed spontaneous electrographic discharges with high 
amplitude and duration (Figure 1C,D), which were inhibited 
by acute administration of 100 µmol/L valproic acid (VPA; 
P <  .001; n = 3), 50 µmol/L FEN (P <  .0001; n = 9), or 
10 µmol/L DZP (P < .01; n = 8; Figure 1D). We then per-
formed electroencephalography (EEG) with alternating peri-
ods of stimulus deprivation or photostimulation, by recording 
larvae in the dark or delivering a 10-Hz sine wave flashing 
light. Spectral EEG analyses revealed that scn1labmut/mut lar-
val (n = 11) energy profiles differed significantly from het-
erozygous (n = 8) and WT counterparts (P < .0001; n = 11). 
F I G U R E  2  Single-cell RNA-Seq data reveals changes in brain composition. A, The 2508 clearly identified cells were clustered and cell 
identities inferred by cell type-specific scores (Figure S4) based on marker genes (Table S1). Interestingly, distinct astrocytic clusters were 
identified that indicate maturation of cells (Figure S4). OPC, oligodendrocyte progenitor cells. B, The brain composition exhibits an increase in 
radial glia at 7 days postfertilization (dpf) for both cell lines and a doubled percentage of reactive astrocytes in scn1labmut/mut cells. The strongly 
reduced number of oligodendrocytes at 7 dpf probably results from damage during cell isolation and corresponding leakage of mRNAs (Figure 
S5). Cell clusters presented here are from pooled larval brains derived from wild type or homozygotes. tSNE, T-distributed Stochastic Neighbor 
Embedding
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In particular, energy distribution at high frequencies (>100 
Hz) was greater (Figure 1E).
3.2 | Brain composition analysis
We performed scRNA-Seq analysis using our Drop-Seq 
pipeline (see Supplementary Methods in Data S1). Epithelial 
cells formed a distinct subpopulation (light red cluster), 
and neuronal- and glia-related clusters were separated well. 
Astrocytes formed subclusters, and radial glia exhibited a 
specialized expression profile leading to a distinct cluster 
(Figure 2A). Comparison of cell type matching with sam-
ple identity (Figure S5) did not indicate a scn1labmut/mut-
specific neuronal expression profile but reduced astrocytic 
maturation. Increased vascularization became apparent from 
the increased number of erythrocytes at 7 dpf (Figure 2B). 
Oligodendrocyte absence at 7 dpf for both conditions is 
related to the exclusion of leaking cells, as the majority of 
these were associated with 7-dpf samples and careful evalu-
ation of the corresponding expression profiles indicated their 
oligodendrocytic origin by the remaining her4.1 transcripts 
(Figure S5). The relative decrease in the neuronal subpopula-
tion was also caused by an increase in astrocytes in both lines 
where, in particular, radial glia appeared to be enriched in 
scn1labmut/mut larvae.
3.3 | Reduced GABAergic neurons and 
increased gliosis
We investigated GABAergic and glutamatergic neurons by 
calculating subtype-specific scores based on relative marker 
gene expression (Table S1, Figure S6). Glutamatergic 
scores were similar for scn1labmut/mut and WT, exhibit-
ing an increase from 4 to  7 dpf, where only the increase 
F I G U R E  3  Single-cell RNA-Seq data reveal changes in γ-aminobutyric acidergic (GABA) and glutamatergic profiles defined by 
corresponding marker genes during development and between conditions. A, The glutamatergic score indicates a stronger increase of glutamatergic 
profiles in wild-type (WT) than in scn1labmut/mut larvae from 4 to 7 days postfertilization (dpf). B, The GABA-related score indicates a significant 
decrease in neurons of scn1labmut/mut larvae and an increase in WT from 4 to 7 dpf, leading to a significant difference between the conditions. 
C, Combining these scores to investigate the balance between GABA- and glutamate-related neurons shows a dramatic change in scn1labmut/mut 
larvae, where the ratio between GABAergic and glutamatergic profiles is reduced by nearly 50% at 7 dpf compared to 4 dpf, whereas in WT only a 
minor reduction is observed. This results in a significant difference between scn1labmut/mut and WT larvae at 7 dpf and may indicate an underlying 
mechanism of epileptogenesis. D, The increased number of reactive astrocytes found in scn1labmut/mut do also exhibit an increased gliosis activity 
defined by corresponding marker genes (Table S1) at 7 dpf, as indicated by differentially expressed gene analysis. E, At 6 dpf, scn1labmut/mut larvae 
had an increased expression of glutamatergic (vglut1), GABAergic (gad67), and postmitotic (elavl3) neuronal markers compared to WT siblings, 
as measured by real-time quantitative polymerase chain reaction. F, Upregulation of the excitatory system (as observed by normalization of vglut1 
over elavl3), but not the inhibitory system (as observed by normalization of gad67 over elavl3), indicates a shift in the GABA/GLUT population 
ratios in the brain of scn1labmut/mut larvae. *P < .05, **P < .01. ns, not significant
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in WT was statistically significant (Figure 3A). In contrast, 
GABAergic scores revealed significant differences during 
development and between WT and mutant. Whereas the 
GABAergic score of scn1labmut/mut larvae showed a signifi-
cant reduction from 4 to 7 dpf, WT larvae exhibited a signif-
icant increase in GABAergic marker levels at 7 dpf (Figure 
3B). Consequently, scn1labmut/mut larvae had significantly 
reduced GABAergic marker expression at 7 dpf compared 
to WT. The similar expression of glutamatergic markers and 
the significant differences in the GABAergic score led to 
a distinct shift in the ratio between GABAergic and gluta-
matergic scores (Figure 3C). Whereas the ratio was slightly 
reduced in WT (10%), scn1labmut/mut larvae exhibited a re-
duction of 43% at 7 dpf and a significant decrease (19%) in 
WT at 7 dpf.
To investigate the increased number of reactive astro-
cytes in scn1labmut/mut larvae at 7 dpf further, we performed 
differentially expressed gene analysis and found an enrich-
ment of gliosis-related genes. We calculated a gliosis score 
based on marker genes (Table S1) and found a trend for 
higher gliosis activity in reactive astrocytes of scn1lab-
mut/mut larvae (Figure 3D, Figure S6). To test whether the 
decrease in GABAergic cells correlated with a change in 
neuronal morphology at the expression level, we targeted 
axonogenesis-related genes (Table S1) in the scRNA-Seq 
data. Although we could not find a significant effect on 
branching expression levels, we observed a trend toward 
downregulation of neuronal branching genes in the mutant 
(18%), whereas WT larvae exhibited a nonsignificant re-
duction of 6% (Figure S7).
To confirm that the distinct EEG energy profile of scn-
1labmut/mut is caused by increased synaptic activity due 
to reduced inhibitory tone, we used real-time quantita-
tive PCR to quantify glutamatergic (vglut1), GABAergic 
F I G U R E  4  Dendritic arborization in scn1labmut/mut larvae. A, scn1labmut/mut larvae show a reduced number of dendritic arbors at 3 days 
postfertilization (dpf). Significance of differences was calculated using an unpaired, two-tailed t test. *P < .05. B, Representative images of 
dendritic arbors in the neuropil of wild-type (WT) and scn1labmut/mut larvae at 3 dpf. Scale bars = 25 μm. C, Reduction in dendritic arborization 
in scn1labmut/mut larvae observed at 6 dpf can be rescued by the addition of 50 μmol/L of fenfluramine (FEN), but not 10 μmol/L of diazepam 
(DZP), from 3 dpf until 6 dpf. Significance of differences was calculated using one-way analysis of variance with Sidak post hoc test. *P < .05, 
***P < .001. D, Representative images of dendritic arbors in the neuropil of WT and scn1labmut/mut larvae at 6 dpf, with or without prior incubation 
in 50 μmol/L of FEN or 10 μM of DZP from 3 dpf onward. Scale bars = 25 μm
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(gad67), and postmitotic (elavl3) neuronal markers in lar-
val brains. Homozygous scn1labmut/mut had increased ex-
pression of all markers compared to WT (P < .001, elavl3/
actb2 and vglut1/actb2; P  <  .05, gad67/actb2; n  =  7; 
Figure 3E). However, normalization of vglut1 expression 
against elavl3 indicated upregulation of excitatory mark-
ers (P < .05), whereas normalization of gad67 expression 
against elavl3 showed no differences between scn1labmut/
mut and WT (P > .05; Figure 3F).
3.4 | Neuronal defects restored by FEN
The amplitude difference in the power spectrum observed 
between scn1labmut/mut and WT indicated possible alteration 
in optic tectum cytoarchitecture. We therefore quantified 
dendritic arborization in GABAergic neurons, as reduced 
branching would explain reduced inhibitory tone. Sholl 
analysis revealed a 30% decrease (P < .05; n = 16) in den-
dritic arborization of GABAergic tectal neurons of 3 dpf sc-
n1labmut/mut larvae compared to WT (n = 16; Figure 4A,B). 
By 6 dpf, dendritic arbors were reduced by 40% (P < .001; 
n = 15; Figure 4C,D). As acute FEN treatment effectively 
suppressed seizures in previously described zebrafish DS 
models,16,28 we tested whether chronic FEN administration 
might affect dendritic morphology. We administered 50 µM 
FEN chronically for 3 consecutive days, starting at 3 dpf, 
prior to seizure onset. Chronic treatment of scn1labmut/mut 
larvae with FEN significantly (P < .05; n = 15) abrogated 
the reduction in dendritic arborization, whereas chronic 
treatment of WT did not induce any changes (P  >  .05; 
n = 15; Figure 4C,D). Chronic treatment of scn1labmut/mut 
larvae with DZP attenuated seizures but showed no amelio-
ration of reduced arborization (Figure 4C,D).
We also evaluated changes in cell proliferation through 
BrdU labeling in scn1labmut/mut brains. We observed an increase 
(P < .01; n = 8) in BrdU-positive cells, compared to WT at 6 
dpf (n = 16; Figure 5). To test whether FEN might also regulate 
cell proliferation, we exposed scn1labmut/mut larvae to FEN as 
described above. FEN restored (P < .05; n = 9) the number of 
BrdU-positive tectal cells to untreated WT baseline. FEN treat-
ment of WT also increased (P < .0001; n = 7) BrdU-positive 
cells when compared to untreated WT controls (Figure 5).
4 |  DISCUSSION
4.1 | New zebrafish mutant to study DS 
epileptogenesis
The scn1lab mutant described here replicates classic features 
of DS and recapitulates both previously described pheno-
types for other zebrafish scn1lab loss-of-function models and 
Scn1a mouse mutants.4,6,27,28 didy homozygotes, however, 
F I G U R E  5  Proliferation of cells in the optic tectum of scn1labmut/mut larvae. A, At 6 days postfertilization (dpf), scn1labmut/mut larvae showed 
an increased number of proliferating cells in the optic tectum, as measured by BrdU-positive cells in 30-μm-thick optical sections. Incubation of 
larvae in 50 μmol/L of fenfluramine (FEN) from 3 dpf onward resulted in an increased number of BrdU-positive cells in wild-type (WT) larvae at 6 
dpf, while reducing the number to untreated WT levels in the scn1labmut/mut larvae. Statistical significance was calculated using multiple unpaired, 
two-tailed t tests. *P < .05, **P < .01, ****P < .0001. B, Cartoon representation of the head of a 6-dpf larva, indicating the position of the optic 
tectum where proliferation was measured. C, Representative z-slices of masked optic tecta with BrdU staining of WT and scn1labmut/mut larvae at 6 
dpf, with or without prior incubation in 50 μmol/L of FEN from 3 dpf onward. Squares indicate the location of the zoomed-in, split-channel images 
to the right. Scale bars = 50 μm
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survive until 10 dpf,28 whereas scn1labmut/mut larvae survive 
until 14 dpf. Moreover, seizures were only reported in didy 
homozygotes, whereas seizures were also observed in scn-
1labwt/mut heterozygotes, possibly attributable to differences 
in genetic background or the nature of the mutation (non-
sense vs missense).
4.2 | Increased brain excitability
The higher energy distribution observed in scn1labmut/mut 
brains, both after photostimulus and under dark conditions, 
indicated that the summation signal of dendritic potentials 
was excitatory. This is not surprising, given the development 
of spontaneous seizures, but the finding that this is mostly 
represented in the high-frequency gamma band was sugges-
tive not only of increased synaptic activity but possibly of 
decreased inhibitory tone. Neuronal hyperactivity, driven 
primarily by reduced background inhibition, can be caused 
by various mechanisms. For example, abnormal gamma-
band activity has been observed in schizophrenia patients 
and related animal disease models as a result of impaired 
GABAergic neurotransmission, particularly in parvalbumin-
expressing neurons.29 Regarding SCN1A-derived disorders, 
two mechanisms underlying neuronal hyperexcitability have 
been proposed: impaired interneuron sodium channel activ-
ity or increased pyramidal neuron excitability.30 With regard 
to the former, studies on mouse Scn1a mutants support the 
hypothesis of disinhibition resulting from decreased Nav1.1 
function in interneurons.9,31
4.3 | GABAergic neuron loss
There is sufficient evidence that loss of GABAergic neurons 
is a consistent finding among all models of acquired epilepsy 
including kindling, status epilepticus, and traumatic brain 
injury as well as a frequently observed hallmark of tempo-
ral lobe epilepsy (TLE).32‒37 Furthermore, selective loss of 
GABAergic neurons can also give rise to an epileptic state 
in genetic models. Mice with loss of Dlx1, which encodes 
a transcription factor regulating GABAergic interneuron de-
velopment, develop epilepsy as a result of a time-dependent 
reduction in the number of these neurons within the cerebral 
cortex and hippocampus.38
A previous study reported no evident loss of GABAergic 
neurons in the zebrafish scn1lab mutant didy.27 Possible ex-
planations for this discrepancy in cellular phenotype between 
the models are differences in mutation type and/or the genetic 
background. Another plausible explanation is that we ana-
lyzed GABAergic neuron population dynamics at a later de-
velopmental stage (7 dpf instead of 5 dpf as carried out in the 
didy study) and therefore after a longer period of spontaneous 
recurring seizures. Our data at 4 dpf corroborate with the didy 
study findings of no evident cell loss. Interestingly, our data 
indicate that there is a slight increase in GABAergic neurons 
at this earlier time point in the mutant, indicating changes 
in cell proliferation in the mutant during brain development. 
Furthermore, we found no difference in glutamatergic marker 
levels between the conditions but an increase from 4 to 7 dpf. 
Thus, by 7 dpf, the decrease in the GABAergic neuron sig-
nature and the increase in glutamatergic signature indicated a 
shift in the GABA/GLUT ratio in scn1labmut/mut larvae, pro-
viding additional evidence for decreased inhibitory tone.
Importantly, a proportion of GABAergic neurons still re-
main in mutant larvae, as has been observed in Scn1a mouse 
models, other models of acquired epilepsy, and human TLE. 
Alterations in the remaining GABAergic neurons of these 
mammalian models have been proposed as contributors to 
epileptogenesis. Critical changes resulting in the establish-
ment of an epileptic state include impaired function of re-
maining GABAergic neurons and morphological changes 
that eventually lead to aberrant circuitry.39
4.4 | Reduced dendritic arborization
The significant reduction in dendritic branching of 
GABAergic neurons prior to seizure onset in our DS model 
shows that structural deficits are established well before the 
epileptic phenotype arises. This indicates that seizures per 
se are not the primary cause of the observed arborization 
defects and that the converse may be true; reduced arbori-
zation is a possible primary mechanism underlying seizures 
in DS. Importantly, these defects arose when GABA was 
still excitatory, that is, prior to the GABA developmen-
tal switch, which occurs at 2.5 dpf in zebrafish. The early 
branching defects in GABAergic neurons are thus likely to 
be due to the inability of these neurons to propagate action 
potentials, which in turn impairs strengthening and pruning 
of synaptic connections. In general, dysfunctional voltage-
gated sodium channels would lead to impaired action po-
tentials and current in GABAergic inhibitory neurons,6,39 
lowering inhibitory tone and consequently increasing over-
all network excitability, which would dramatically alter 
plasticity, morphology, network dynamics, and functional 
topology of the neural circuitry. A similar mechanism was 
proposed for the zebrafish scn1lab mutant didy, originally 
described as displaying an abnormal optokinetic response 
due to its inability to sustain saccade eye movements when 
presented with a repeating visual stimulus pattern.40 The 
authors postulated that depleting scn1a channel function in 
didy could potentially reduce channel density, in turn re-
sulting in prolonged stimulation that would eventually de-
plete the pool of activatable channels and ultimately render 
neurons unexcitable.
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4.5 | FEN treatment rescues dendritic 
arborization defects
FEN, a serotonin 5-HT2A and 5-HT2C receptors agonist, is 
highly effective in diminishing seizures in reported zebrafish 
DS models. Surprisingly, there are no reports describing ef-
fects of chronic or acute FEN treatment in DS rodent mod-
els. A recent study that evaluated selective 5-HT2C agonists 
lorcaserin, CP809101, and FEN in multiple acute rodent sei-
zure models (maximum electroshock seizure [MES], MES 
threshold, 6-Hz electrical convulsive seizure, pentylenetetra-
zole, and amygdala kindling), showed that with the excep-
tion of FEN-mediated tonic seizure inhibition in the MES 
rat test, there was no antiseizure effect for all compounds in 
all other tests.41 The authors concluded that early develop-
mental genetic models might be more appropriate for study 
of certain drug leads, indicating a need to consider integrat-
ing additional animal models into preclinical drug discovery 
pipelines.
Chronic treatment with FEN prevents cell overprolif-
eration in scn1labmut/mut larvae. However, in WT larvae 
it increases cell proliferation. These results corroborate 
previous findings that showed neurogenesis-stimulating 
activity of antidepressants in the dentate gyrus.42 The 
role of serotonin in regulating interneuron morphol-
ogy has previously been shown. Inhibition of serotonin 
synthesis in rat embryos with para-chlorophenylalanine 
disrupted pyramidal neuron maturation within the so-
matosensory cortex by reducing dendritic arborization.43 
Benzodiazepines such as DZP and clobazam have been 
used to treat DS.18 Our data suggest that FEN activity 
is specific and not simply due to seizure inhibition, as 
chronic treatment using DZP did not restore dendritic 
arbor numbers to normal.
Dendritic arborization defects have also been reported 
for Scn1aE1099X/+ and Scn1bC121W/+ mice.11,44 Scn1aE1099X/+ 
mice display progressively reduced dendritic arborization 
and excessive spines in GABAergic hippocampal dentate 
gyrus neurons, whereas Scn1bC121W/+ mice exhibit reduced 
arborization in subicular pyramidal neurons. These mor-
phological abnormalities, however, were analyzed coin-
cident with (ie, not prior to) developmental spontaneous 
seizure onset. It is therefore unclear whether arborization 
defects in these models were a key trigger for epileptogen-
esis or a consequence thereof. Clearly, further investigation 
is warranted to determine the exact role of dendritic ar-
borization in DS pathogenesis. Such studies would require 
dendrite morphology analysis in our DS model at later de-
velopmental stages, to allow for sufficient drug washout 
after chronic FEN or DZP administration (to rule out acute 
seizure inhibition from residual drug), ideally resulting in 
significant seizure reduction or freedom in FEN-rescued 
but not DZP-treated larvae.
4.6 | Gliosis
Radial glial cells are more abundant in scn1lab mutants com-
pared to WT, with a doubling of reactive astrocytes in the 
mutant relative to WT, indicating a trend toward increased 
gliosis. Reactive astrocytes increase in number as a conse-
quence of epileptic events but are also suggested to play a 
functional role in the causation of seizures, for instance, after 
brain trauma.45 Our scRNA-Seq results are in line with a 
previous study that compared RNA-Seq data obtained from 
Scn1a± mice on two different strains. Half of differentially 
expressed genes shared between the two models were as-
sociated with astrogliosis, including genes upregulated in 
response to human and rodent seizures or traumatic brain 
injury.46
As mentioned, heterozygous scn1lab mutant larvae de-
scribed in this study also display frequent seizures yet are 
fertile and survive to adulthood. This could prove useful for 
analyzing Scn1a dysfunction during later stages of epilepto-
genesis for studying comorbid features and for testing dis-
ease-modifying activity of drugs in the context of a mature 
brain. The astrogliosis phenotype is also worth characterizing 
further. Notably, a study that performed electrophysiological 
recordings on acute brain slices from Scn1a± mice found 
that, at later developmental stages, parvalbumin-positive 
fast-spiking basket cell interneuron excitability normalized. 
The results of this study implied that impairing action poten-
tial generation by parvalbumin-positive fast-spiking basket 
cell interneurons contribute to the initial epilepsy phenotype 
but may not be the sole mechanism that drives later, chronic 
epilepsy in DS.47 It is equally important, however, to con-
sider that the variable severity and expressivity of the murine 
Scn1a± epilepsy phenotype is highly strain dependent.48,49 
Therefore, it will be interesting to explore whether stabiliza-
tion of interneuron activity can be recapitulated in the zebraf-
ish scn1labwt/mut.
This study describes a new zebrafish scn1a channelopathy 
model that recapitulates many aspects of DS and may prove 
useful in identifying other disease mechanisms such as the 
role of neuron-glia interaction and glutamatergic neurons in 
the process of epileptogenesis or the development of other 
associated comorbidities. These data illustrate the utility of 
zebrafish genetic epilepsy models in elucidating early mech-
anisms leading to an epileptogenic state. The remarkable ef-
ficacy of FEN in this DS model demonstrates the utility of 
zebrafish in uncovering potential disease-modifying activity 
of drug leads.
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